ClinicalTrials.gg
TerminatedNCT03139032Updated Dec 31, 2020Results posted

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

A Phase 2 interventional study of APD334 in Inflammatory Bowel Diseases and Skin Extra-intestinal Manifestations, sponsored by Arena Pharmaceuticals. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-12-31.

Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision to terminate the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Inflammatory Bowel Diseases by Pfizer — none open to participants now, none under way, none of them phase 3. Inflammatory Bowel Diseases · Pfizer.

Enrollment
10th of 11
1 · median 44
Started
2017
with 1 other
Phase 2
2 of 15
none open now
Registered
8th of 15
by date

Among the 15 studies in Inflammatory Bowel Diseases by Pfizer, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 8th registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 424 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

None of the 15 studies in Inflammatory Bowel Diseases by Pfizer is open now. The open studies under Inflammatory Bowel Diseases, anywhere →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Inflammatory Bowel Diseases by Pfizer as a file.
02

Study summary

The purpose of this phase 2a, proof of concept, open-label clinical study is to evaluate the efficacy and safety of etrasimod (APD334) in inflammatory bowel disease patients with active skin extra-intestinal manifestations.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Skin Extra-intestinal Manifestations
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female (18-80 years).
  2. Able to provide a signed prior to any study related procedure being conducted.
  3. Considered to be in stable health in the opinion of the investigator as determined by:

    1. A pre-study physical examination with no abnormalities unrelated to IBD.
    2. Vital signs at screening: pulse rate ≥ 55 bpm, systolic blood pressure ≥ 90, and diastolic blood pressure ≥ 55 mmHg.
    3. Liver function tests (/AST, and alkaline phosphatase) \< 2x the .
    4. All other pre-study clinical laboratory findings within normal range, or if outside of the normal range are not deemed clinically significant in the opinion of the investigator.
    5. 12-lead showing no clinically significant abnormalities in the opinion of the investigator (for confirmation please refer to exclusion criterion # 22).
    6. A chest x- ray showing no evidence of active pulmonary disease (a chest x-ray taken within the previous 12 months from the screening visit may also be used).
    7. Ophthalmology evaluation (by an ophthalmologist) without evidence of macular edema, supported with optical coherence tomography where available (dependent on site capability) no later than 3 months prior to screening.
  4. Patients receiving stable treatment for IBD and EIM.
  5. Diagnosis of active psoriasis, erythema nodosum or pyoderma gangrenosum by Investigator assessments. After the enrollment of 10 patients with active EIM, patients with active psoriasis due to anti TNF-alpha therapy can also be included.
  6. Diagnosis of ulcerative colitis or Crohn's disease established prior to screening by clinical and endoscopic evidence.
  7. Eligible male and female patients must agree not to participate in a conception process (i.e. active attempt to let female partner to become pregnant or to impregnate, sperm donation, oocyte donation, in vitro fertilization) for at least 30 days after the last dose of study drug.

Non-sterile patients who are sexually active must take adequate measures.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of abdominal abscess or toxic megacolon at the screening visit.
  2. Patients with history of extensive colitis or pancolitis (duration > 8 years) or left-sided colitis (duration > 12 years) must have documented evidence that a surveillance colonoscopy was performed within 12 months of the initial screening visit (if not, the patient should undergo a colonoscopy in lieu of a flexible proctosigmoidoscopy during screening).
  3. Previous extensive colonic resection (subtotal or total colectomy).
  4. Current evidence of adenomatous colonic polyps that have not been removed.
  5. Current evidence of colonic mucosal dysplasia.
  6. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine or stoma.
  7. Clinical significant infection as judged by the investigator in the previous 6 weeks before enrollment.
  8. Evidence of or treatment for C. difficile infection within 60 days, or other intestinal pathogen within 30 days, prior to randomization.
  9. Exposure to natalizumab or rituximab within 5 half-lives prior to randomization.
  10. Treatment of underlying disease within 30 days prior to randomization (5-ASA, , TNF-alpha inhibitors, probiotics, antidiarrheals, azathioprine and 6-mercaptopurine may be allowed under certain conditions).
  11. Receipt of any agent within 30 days or 5 half-lives (whichever is longer) prior to randomization.
  12. Currently require or are anticipated to require surgical intervention for IBD during the study.
  13. Abnormal (\< 80% of predicted values) (FEV1) or forced vital capacity (FVC).
  14. Infection with virus anytime in the past; confirmed active infection with virus at screening.
  15. Active or latent tuberculosis (TB), regardless of treatment history, as evidenced by any of the following:

    1. History of TB
    2. A positive diagnostic TB test within one month of randomization
    3. Chest X-ray within 12 months of randomization in which active or latent TB cannot be excluded.
  16. Any known history of congenital or acquired immunodeficiency.
  17. extra-intestinal infection (e.g., pneumonia, pyelonephritis) within 30 days prior to randomization.
  18. Recent history (within 6 months of screening visit) of cardio- or cerebrovascular disease, acute coronary syndrome, myocardial infarction, unstable angina, cerebro-vascular accident, including .
  19. Any surgical procedure requiring general anesthesia within 30 days prior to randomization or plans to undergo major surgery during the study period.
  20. History of retinal macular edema.
  21. History of or signs and symptoms of progressive multifocal leukoencephalopathy (PML) as assessed by the PML checklist.
  22. History or presence of cardiac arrhythmia, conduction system disease, or use of Class Ia or Class III anti arrhythmic agents, or baseline ≥ 500 msec.
  23. Infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection within 4 weeks of screening.
  24. History of more than one episode of herpes zoster or any episode of disseminated zoster.
  25. Without documented positive varicella zoster virus (VZV) IgG antibody status or who have completed VZV vaccination within 30 days prior to randomization.
  26. Receipt of within 4 weeks prior to screening.
  27. History of lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorder, or multiple myeloma.
  28. History of except for adequately treated basal cell skin cancer.
  29. History of severe allergic or anaphylactic reactions requiring medical attention.
  30. Current or recent history (within one year prior to randomization) of alcohol dependence or illicit drug use.
  31. History of clinically significant leukopenia or lymphopenia at screening.
  32. Active psychiatric problems that, in the investigator's opinion, may interfere with compliance with the study procedures.
  33. History of any clinically significant medical condition that, in the investigator's opinion, would preclude participation in the study.
  34. Use of moderate to strong inhibitors of CYP2C9.
  35. History of severe renal or hepatic impairment.
  36. Inability to attend all the study visits or comply with study procedures.
  37. Prior exposure to etrasimod (APD334).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    APD334

    APD334 active treatment for 12 weeks.

    Drug: APD334

Interventions

  • DrugAPD334

    APD334 active treatment for 12 weeks.

    Also known as: Etrasimod

06

What researchers measure

Primary outcomes

  1. Exploratory Endpoint - Change From Baseline in Endoscopic Improvement/Histologic Healing Using Endoscopy or Flexible Proctosigmoidoscopy

    Only if there are signs of inflammation at screening another evaluation was planned to be performed at week 12.

    Time frame: Weeks 12

  2. Exploratory Endpoint - Change From Baseline in Level of Fecal Calprotectin

    Time frame: Weeks 4, 8, and 12

  3. Exploratory Endpoint - Change From Baseline in Physician Global Assessments for Active Skin Extra-intestinal Manifestations (EIM) (PG, EN and Psoriasis)

    Time frame: Weeks 1, 2, 4, 8, and 12

  4. Exploratory Endpoint - Change From Baseline in Patient Global Assessments for Active Skin EIM

    Time frame: Weeks 1, 2, 4, 8, and 12

  5. Exploratory Endpoint - Change From Baseline in the Dermatology Life Quality Index Score

    Time frame: Weeks 1, 2, 4, 8, and 12

  6. Exploratory Endpoint - Change From Baseline in Inflammatory Bowel Disease Questionnaire Score

    Time frame: Weeks 2, 4, 8, and 12

  7. Exploratory Endpoint - Change From Baseline in C-reactive Protein

    Time frame: Weeks 1, 2, 4, 8, 12 and the 2-week follow-up visit

  8. Exploratory Endpoint - Change From Baseline in Leucocyte Characterization

    Time frame: Weeks 8 and 12

  9. Exploratory Endpoint - Change From Baseline in Stool Frequency at Ulcerative Colitis Endpoint

    Time frame: Weeks 1, 2, 4, 8, and 12

  10. Exploratory Endpoint - Change From Baseline in Rectal Bleeding at Ulcerative Colitis Endpoint

    Time frame: Weeks 1, 2, 4, 8, and 12

  11. Exploratory Endpoint - Change From Baseline in Physicians Global Assessments at Ulcerative Colitis Endpoint

    Time frame: Weeks 1, 2, 4, 8, and 12

  12. Exploratory Endpoint - Change From Baseline in Lymphocyte Counts

    Time frame: Weeks 1, 2, 4, 8, and 12

  13. Exploratory Endpoint - Change From Baseline in Disease Activity Score at Crohn's Disease Endpoint

    Time frame: Weeks 1, 2, 4, 8, and 12

  14. Exploratory Endpoint - Change From Baseline in Psoriasis Area and Severity Index at Psoriasis Endpoint

    Time frame: Weeks 1, 2, 4, 8, and 12

  15. Exploratory Endpoint - Changes in Degree of Immune Cell Infiltration as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)

    Time frame: Weeks -1, 8, and 12.

  16. Exploratory Endpoint -Changes in Levels of Cytokine Expression as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)

    Time frame: Weeks -1, 8 and 12.

Other outcomes

  1. Safety Measured by Number of Participants With Adverse Events and Serious Adverse Events

    Planned safety evaluations included clinical laboratory tests (chemistry, hematology, and urinalysis), vital signs (blood pressure, pulse, respiratory rate, and oral temperature), physical examination (assessment of general appearance, skin, head \[eyes, ears, nose and throat\], neck, thyroid, lungs, heart, abdomen, back, lymph nodes, and extremities, and body weight), 12-lead electrocardiograms, adverse event reporting, concomitant medication, and lymphocyte counts.

    Time frame: From date of first dose of study treatment to the safety follow-up visit, approximately 14 weeks

07

Results

Posted Dec 31, 2020
Limitations and caveats
Due to limited enrollment (N=1), this clinical trial was terminated by the Sponsor and no efficacy analyses were conducted. To protect the single participant's privacy, demography and efficacy data are not reported.

Participant flow

Participant flow — Overall Study
MilestoneEtrasimod
Started1
Completed1
Not completed0

Outcome measures

PrimaryExploratory Endpoint - Change From Baseline in Endoscopic Improvement/Histologic Healing Using Endoscopy or Flexible Proctosigmoidoscopy

Only if there are signs of inflammation at screening another evaluation was planned to be performed at week 12.

Time frame:
Weeks 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Level of Fecal Calprotectin
Time frame:
Weeks 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Physician Global Assessments for Active Skin Extra-intestinal Manifestations (EIM) (PG, EN and Psoriasis)
Time frame:
Weeks 1, 2, 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Patient Global Assessments for Active Skin EIM
Time frame:
Weeks 1, 2, 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in the Dermatology Life Quality Index Score
Time frame:
Weeks 1, 2, 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Inflammatory Bowel Disease Questionnaire Score
Time frame:
Weeks 2, 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in C-reactive Protein
Time frame:
Weeks 1, 2, 4, 8, 12 and the 2-week follow-up visit

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Leucocyte Characterization
Time frame:
Weeks 8 and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Stool Frequency at Ulcerative Colitis Endpoint
Time frame:
Weeks 1, 2, 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Rectal Bleeding at Ulcerative Colitis Endpoint
Time frame:
Weeks 1, 2, 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Physicians Global Assessments at Ulcerative Colitis Endpoint
Time frame:
Weeks 1, 2, 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Lymphocyte Counts
Time frame:
Weeks 1, 2, 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Disease Activity Score at Crohn's Disease Endpoint
Time frame:
Weeks 1, 2, 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Change From Baseline in Psoriasis Area and Severity Index at Psoriasis Endpoint
Time frame:
Weeks 1, 2, 4, 8, and 12

No measurements were reported for this outcome.

PrimaryExploratory Endpoint - Changes in Degree of Immune Cell Infiltration as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)
Time frame:
Weeks -1, 8, and 12.

No measurements were reported for this outcome.

PrimaryExploratory Endpoint -Changes in Levels of Cytokine Expression as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)
Time frame:
Weeks -1, 8 and 12.

No measurements were reported for this outcome.

Other pre-specifiedSafety Measured by Number of Participants With Adverse Events and Serious Adverse Events

Planned safety evaluations included clinical laboratory tests (chemistry, hematology, and urinalysis), vital signs (blood pressure, pulse, respiratory rate, and oral temperature), physical examination (assessment of general appearance, skin, head \[eyes, ears, nose and throat\], neck, thyroid, lungs, heart, abdomen, back, lymph nodes, and extremities, and body weight), 12-lead electrocardiograms, adverse event reporting, concomitant medication, and lymphocyte counts.

Time frame:
From date of first dose of study treatment to the safety follow-up visit, approximately 14 weeks
Reported as:
Count of participants · Participants
Safety Measured by Number of Participants With Adverse Events and Serious Adverse Events
ParticipantsEtrasimod
Safety Measured by Number of Participants With Adverse Events and Serious Adverse Events0

Adverse events

Collected over From first dose of study treatment until the follow-up safety visit, approximately 14 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etrasimod0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)Etrasimod
Between 18 to 80 years1
Sex: Female, Male
Sex: Female, Male(Participants)Etrasimod
FemaleNA
MaleNA
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Etrasimod
Hispanic or LatinoNA
Not Hispanic or LatinoNA
Unknown or Not ReportedNA
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Etrasimod
American Indian or Alaska NativeNA
AsianNA
Native Hawaiian or Other Pacific IslanderNA
Black or African AmericanNA
WhiteNA
More than one raceNA
Unknown or Not ReportedNA
08

Study locations

3 sites
  • Arena 2001
    Leuven, Belgium
  • Arena 1001
    Hamburg, Germany
  • Arena 3001
    Belgrade, Serbia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Dec 2017, 4 months.

Results were first posted in Dec 2020, 3 years after primary completion. A results delay was requested in May 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2017
First posted
May 3, 2017
StartActual
Jul 17, 2017
Primary completionActual
Dec 6, 2017
CompletionActual
Dec 6, 2017
Results delay requested
May 13, 2019
Results first posted
Dec 31, 2020
Last update
Dec 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03139032
Responsible party
Sponsor
First posted
May 3, 2017
Start date
Jul 17, 2017
Primary completion
Dec 6, 2017
Completion
Dec 6, 2017
Results posted
Dec 31, 2020
Last update
Dec 31, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion